Rivaroxaban

IUPAC name

5-Chloro-N-[[(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl]methyl]thiophene-2-carboxamide

CAS No.

366789-02-8

Molecular Weight

435.88 g·mol−1

Molecular Formula

C19H18ClN3O5S

 

 

Mechanism Of Action:

It’s a selective inhibitor of factor Xa (FXa), and is an inhibitor of free FXa and prothrombinase activity, and indirectly inhibits platelet aggregation induced by thrombin.

Indication:

  • Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation (NVAF)

  • Treatment of Deep Vein Thrombosis (DVT) & Pulmonary Embolism (PE)

  • Reduction in the Risk of Recurrence of DVT and/or PE

  • Prophylaxis of DVT Following Hip or Knee Replacement Surgery

  • Prophylaxis of Venous Thromboembolism in Acutely Ill Medical Patients at Risk for Thromboembolic Complications Not At High Risk of Bleeding

  • Reduction of Risk of Major Cardiovascular Events in Patients with Chronic Coronary Artery Disease (CAD) or Peripheral Artery Disease (PAD)

  • Treatment of venous thromboembolism, and Prophylaxis of recurrent venous thromboembolism in in pediatric patients.